Amgen (AMGN): FY26 Q1 earnings call, Apr 30, 2026
No Kalshi or Polymarket word markets were listed for Amgen’s Apr 30, 2026 earnings call (FY26 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
5 matches for “Artificial Intelligence”; 5 quoted, at least 25 words apart.
…feel about the convergence of technology and biology, including the application of artificial intelligence across the company. Here, too, we're making great progress. And there's…
…we're encouraged that Jay Bradner will build on Dave's accomplishments, leading our artificial intelligence and data activities across the company. I'll have more to say…
…PRMT5 inhibitor. Over the last several years, amidst the rapid advances in artificial intelligence, we've taken a principled approach to reconsidering and augmenting drug discovery…
…capacity for volume growth, including for MariTide's launch. We see technology and artificial intelligence as increasingly important tools to help Amgen operate with greater speed,…
…R&D. So we're thrilled, excited about the progress that we made in artificial intelligence and data under Dave's leadership as well as the other businesses…
Agents: this page as TSV at /api/v1/appearances/amgen:2026-04-30:earnings_call · words: /api/v1/brief?appearance=amgen:2026-04-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP